Compare FSBW & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FSBW | TECX |
|---|---|---|
| Founded | 1936 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.8M | 359.0M |
| IPO Year | 2012 | 2018 |
| Metric | FSBW | TECX |
|---|---|---|
| Price | $42.17 | $21.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $44.00 | ★ $81.20 |
| AVG Volume (30 Days) | 15.6K | ★ 325.0K |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | ★ $140,954,000.00 | N/A |
| Revenue This Year | $10.46 | N/A |
| Revenue Next Year | $4.42 | N/A |
| P/E Ratio | $10.32 | ★ N/A |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $34.61 | $13.70 |
| 52 Week High | $44.22 | $61.07 |
| Indicator | FSBW | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 56.27 |
| Support Level | $41.98 | $17.79 |
| Resistance Level | $44.07 | $22.00 |
| Average True Range (ATR) | 0.88 | 1.19 |
| MACD | -0.10 | 0.16 |
| Stochastic Oscillator | 54.64 | 74.35 |
FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.